Skip to content

A Study on the Etiology and Prognosis of Autism Spectrum Disorder Based on Multi-Omics Integrated Analysis

A Study on the Etiology and Prognosis of Autism Spectrum Disorder Based on Multi-Omics Integrated Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101563
Enrollment
Unknown
Registered
2025-04-27
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

ASD-Repetitive Transcranial Magnetic Stimulation Group ( active stimulation group):Continuous theta burst stimulation ( cTBS)
ASD-Repetitive Transcranial Magnetic Stimulation Group ( sham stimulation group):Sham Stimulation
ASD-Modulated Gut Microbiota Group ( experimental group):Probiotics or Synbiotics
ASD-Modulated Gut Microbiota Group ( placebo group):Placebo
ASD-Blank control group:None
Typical developmental control group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 17 Years

Inclusion criteria

Inclusion criteria: (1) Autism group: aged 3-17 years; Met the DSM-5 criteria for autism spectrum disorder; Wechsler Intelligence Test IQ score greater than 70 points; Right handed; No antipsychotic medication; In addition, patients with gastrointestinal symptoms, antibiotics, probiotics or prebiotics, antacids and other drugs affecting gastrointestinal flora within 3 months before enrollment, DHA, vitamins and other nutritional drugs were not required. (2) Healthy control group: aged 3-17 years; Did not meet the DSM-5 criteria for autism spectrum disorder; Wechsler Intelligence Test IQ score greater than 70 points; Right handed; He was not taking antipsychotic medications.

Exclusion criteria

Exclusion criteria: 1. History of other mental disorders, such as attention deficit hyperactivity disorder, schizophrenia, etc. 2. History of other definite organic brain diseases, such as craniocerebral trauma, epilepsy, infectious diseases, and immune system diseases; 3. Have definite inherited metabolic diseases, such as Down syndrome, fragile x syndrome, Angel syndrome, etc.

Design outcomes

Primary

MeasureTime frame
Autism Behavior Checklist (ABC);Social Responsiveness Scale(SRS);Repetitive Behavior Scale-Revised (RBS-R);Children's Sleep Habits Questionnaire (CSHQ);Magnetic Resonance Imaging (MRI);inflammatory markers in blood;

Secondary

MeasureTime frame
Children's Eating Behaviour Questionnaire(CEBQ);Gastrointestinal Symptom Rating Scale(GSRS);Bristol Stool Scale;Cambridge Neuropsychological Test Automated Battery (Intra-Extra Dimensional Set Shift/ Rapid Visual Information Processing/ Spatial Working Memory);The Developmental Test of Visual-Motor Integration (Beery VMI);The Verbal Fluency Test (VFT);Generalized Anxiety Disorder 7 (GAD-7);Patient Health Questionnaire-9 (PHQ-9);

Countries

China

Contacts

Public ContactYi Huang

West China Hospital of Sichuan University

huangyu@scu.edu.cn+86 189 8060 1705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026